Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma

Cancer Journal from Scientific American

Volumn 3, Issue SUPPL. 1, 1997, Pages

  Thompson, John A ^a,b   Gold, Philip J ^a   Markowitz, Daniel R ^a   Byrd, David R ^a   Lindgren, Catherine G ^a   Fefer, Alexander ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

Immunotherapy; Interferon ; Interleukin 2; Melanoma

Indexed keywords

CARMUSTINE; CISPLATIN; DACARBAZINE; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT INTERLEUKIN 2; TAMOXIFEN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COST; DRUG SELF ADMINISTRATION; FEMALE; FEVER; FLU LIKE SYNDROME; HUMAN; INTERSTITIAL PNEUMONIA; INTRAVENOUS DRUG ADMINISTRATION; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MELANOMA; NEUTROPENIA; OUTPATIENT CARE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 0031424974     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Parker S, Tong T, Bolden S et al. Cancer statistics, 1997. CA Cancer J Clin 1997;47:5-27.
2. Balch CM, Soong SJ, Murad TM. A multifactorial analysis of melanoma. Prognostic factors in 200 melanoma patients with distant metastases (stage III) [part 4]. J Clin Oncol 1983;1:126-134.
3. Mastrangelo M, Berd D, Bellet R Aggressive chemotherapy for melanoma. Principles and Practice of Oncology: PPO Updates 1991;5:1-11.
4. DelPrete S, Maurer L, O'Donnell J et al. Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat Rep 1984;68:1403-1405.
5. McClay EF, Mastrangelo MJ, Berd D et al. Effective combination chemo/hormonal therapy for malignant melanoma: experience with three consecutive trials. Int J Cancer 1992;50:553-556.
6. Legha S, Ring S, Papadopoulous N et al. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer 1989;64:2024-2029.
7. Lichtenstein AK, Pende D. Enhancement of natural killer cytotoxicity by cis-diaminedichloroplatinum (II) in vivo and in vitro. Cancer Res 1986;46:639-644.
8. LoRusso PM, Aukerman SL, Polin L et al. Antitumor efficacy of interleukin-2 alone and in combination with adriamycin and dacarbazine in murine solid tumor systems. Cancer Res 1990;50: 5876-5882.
9. Atkins M, O'Boyle K, Sosman J et al. Multiinstitutional phase II trial of intensive combination chemotherapy for metastatic melanoma. J Clin Oncol 1994;12:1553-1560.
10. Flaherty L, Robinson W, Redman B et al. A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma. Cancer 1993;71:3520-3525.
11. O'Neill P, Hersh E, Warneke J et al. Phase II trial of combination chemotherapy and biological response modification in metastatic melanoma [abstract]. Proceedings of ASCO 1996;15[suppl a]:432.
12. Falkson CI, Ibrahim J, Kirkwood J et al. A randomized phase III trial of dacarbazine (DTIC) versus DTIC + interferon alpha-2b (IFN) versus DTIC + tamoxifen (TMX) versus DTIC + IFN + TMX in metastatic malignant melanoma: an ECOG trial [abstract]. Proceedings of ASCO 1996;15[suppl a]:435.
13. Khayat D, Borel C, Tourani J et al. Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. J Clin Oncol 1993;11:2173-2180.
14. Richards J, Mehta N, Ramming K et al. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 1992;10:1338-1343.
15. Richards J, Mehta N, Schroeder L et al. Sequential chemotherapy/ immunotherapy for metastatic melanoma [abstract]. Proceedings of ASCO 1992;11:346.
16. Legha S, Ring S, Eton O et al. Durable complete responses (CR's) in metastatic melanoma treated with biochemotherapy using cis-platin + vinblastine + DTIC (CVD) and IL-2 + interferon-alpha (IFN-α) [abstract]. Proceedings of ASCO 1995;14[suppl a]:412.
17. Thompson JA, Lee DJ, Lindgren CG et al. Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation. J Clin Oncol 1988;6:669-678.
18. Thompson JA, Gold PJ, Fefer A Outpatient chemoimmunorherapy for the treatment of metastatic melanoma. Semin Oncol 1997; 24[suppl 4]:S44-S48.
19. Papa MZ, Vetto JT, Ettinghausen SE et al. Effect of corticosteroid on the antitumor activity of lymphokine-activated killer cells and interleukin-2 in mice. Cancer Res 1986;46:5618-5623.
20. Vetto JT, Papa MZ, Lotze MT et al. Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids. J Clin Oncol 1987;5:496-503.
21. Gardner M, Altman D: Statistics with Confidence. London: British Medical Journal, 1989:28-33.
22. Sirott MN, Bajorin DF, Wong GY et al. Prognostic factors in patients with metastatic malignant melanoma: a multivariate analysis. Cancer 1993;72:3091-3098.
23. Tartour E, Blay J, Dorval T et al. Predictors of clinical response to interleukin-2-based immunotherapy in melanoma patients: a French multiinstitutional study. J Clin Oncol 1996;14:1697-1703.
24. Kirkwood J, Agarwala S. Systemic cytotoxic and biologic therapy of melanoma. Principles and Practice of Oncology: PPO Updates 1993;7:1-16.
25. Rosenberg S, Lotze M, Yang J et al. Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol 1989;7:1863-1874.
26. Richards J, Gilewski T, Ramming K et al. Effective chemotherapy for melanoma after treatment with interleukin-2. Cancer 1992; 69:427-429.
27. Basu S, Sodhi A. Increased release of interleukin-1 and tumour necrosis factor by interleukin-2-induced lymphokine-activated killer cells in the presence of cisplatin and FK-565. Immunol Cell Biol 1992;70:15-24.
28. Mizutani Y, Bonavida B, Nio Y et al. Enhanced susceptibility of cis-diaminedichloroplatinum-treated K562 cells to lysis by peripheral blood lymphocytes and lymphokine activated killer cells. Cancer 1993;71:1313-1321.
29. Anderson C, Buzaid A, Legha S. Systemic treatments for advanced cutaneous melanoma. Oncology 1995;9:1149-1158.
30. Buzaid AC, Legha S, Bedikian A et al. Neoadjuvant biochemotherapy in melanoma patients (PTS) with local regional metastases (LRM) [abstract]. Proceedings of ASCO 1996;15[suppl a]:434.
31. Hesketh PJ, Harvey WH, Harker WG et al. A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis. J Clin Oncol 1994;12:596-600.